p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer

Sak Kudahetti, Gabrielle Fisher, Laurence Ambroisine, Christopher Foster, Victor Reuter, James Eastham, Henrik Møller, Michael W Kattan, Colin S Cooper, Peter Scardino, Jack Cuzick, Daniel M Berney

Research output: Contribution to journalArticlepeer-review

31 Citations (Scopus)


OBJECTIVE To determine whether p53 is an independent biomarker of prostate cancer outcome against currently used biomarkers in a cohort of conservatively treated prostate cancers with long-term follow-up available. PATIENTS AND METHODS We examined p53 expression by immunohistochemistry in a cohort of 705 patients with clinically localized prostate cancer, who were treated conservatively. Patients were selected through UK Cancer Registries. End-points included prostate cancer death and overall death rates. Standard biological variables, including diagnostic serum PSA, contemporary Gleason scoring, clinical staging and cancer extent were available. p53 expression was measured semi-quantitatively on microscopic examination and compared with current clinical biomarkers. RESULTS p53 over expression was a significant predictor of cause-specific survival (hazard ratio [HR] 2.95, 95% CI 2.05-4.25, P
Original languageEnglish
Pages (from-to)20-4
Number of pages5
JournalBJU International
Issue number1
Publication statusPublished - Jul 2009


  • Aged
  • Cohort Studies
  • Humans
  • Immunohistochemistry
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Prognosis
  • Prostatic Neoplasms
  • Survival Analysis
  • Tumor Markers, Biological
  • Tumor Suppressor Protein p53

Cite this